Literature DB >> 1601986

Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors.

E R Seaquist1, R P Robertson.   

Abstract

To assess the metabolic consequences of hemipancreatectomy in humans, we determined pancreatic beta and alpha cell function in healthy donors. Donors examined cross-sectionally were found to have significantly decreased glucose-induced phasic insulin secretion and arginine-induced insulin and glucagon secretion as compared to age, sex, and body index-matched controls. However, their fasting glucose and insulin values were not different from controls. Similar observations were found in the prospective evaluation of eight donors before and 15 +/- 2 mo after hemipancreatectomy. Beta cell reserve, as measured by glucose potentiation of arginine-induced insulin secretion, was significantly decreased in donors (maximal acute insulin response [AIRmax]: donors = 666 +/- 84 pM vs controls = 1,772 +/- 234 pM) while the PG50 (the glucose value at which the half-maximal response was observed) was the same in the two groups. Donors and controls responded to 60-min continuous intravenous infusions of glucose by reaching identical serum glucose values, despite significantly lower insulin secretory responses in donors. We conclude that hemipancreatectomy in human donors is associated with decreased pancreatic alpha and beta cell function. Since donors generally maintain normoglycemia after hemipancreatectomy despite diminished insulin secretion, our data suggest that healthy humans may compensate for hemipancreatectomy by increasing glucose disposal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601986      PMCID: PMC295869          DOI: 10.1172/JCI115779

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Effects of arterial versus venous sampling on analysis of glucose kinetics in man.

Authors:  E A McGuire; J H Helderman; J D Tobin; R Andres; M Berman
Journal:  J Appl Physiol       Date:  1976-10       Impact factor: 3.531

2.  Reduction of glycemic potentiation. Sensitive indicator of beta-cell loss in partially pancreatectomized dogs.

Authors:  W K Ward; B J Wallum; J C Beard; G J Taborsky; D Porte
Journal:  Diabetes       Date:  1988-06       Impact factor: 9.461

3.  Metabolic effects of living related pancreatic graft donation.

Authors:  J Bolinder; R Gunnarsson; G Tydén; C Brattström; J Ostman; C G Groth
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

4.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  W K Ward; D C Bolgiano; B McKnight; J B Halter; D Porte
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Insulin and glucagon secretion after pancreatectomies. Correlation of secretion and hormonal contents of remaining pancreas.

Authors:  M Gotoh; M Monden; J Okamura; T Mori; K Shima
Journal:  Diabetes       Date:  1989-07       Impact factor: 9.461

6.  Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

Authors:  L Rossetti; G I Shulman; W Zawalich; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

7.  Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia.

Authors:  T Imamura; M Koffler; J H Helderman; D Prince; R Thirlby; L Inman; R H Unger
Journal:  Diabetes       Date:  1988-05       Impact factor: 9.461

8.  Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy.

Authors:  J L Leahy; S Bonner-Weir; G C Weir
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 9.  Type II diabetes, glucose "non-sense," and islet desensitization.

Authors:  R P Robertson
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

10.  Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

Authors:  B B Kahn; G I Shulman; R A DeFronzo; S W Cushman; L Rossetti
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more
  39 in total

1.  To: Godsland IF, Jeffs JA, Johnston DG (2004) loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166.

Authors:  M A Abdul-Ghani; R A DeFronzo
Journal:  Diabetologia       Date:  2005-08-17       Impact factor: 10.122

2.  Uncovering hidden in vivo resonances using editing based on localized TOCSY.

Authors:  Malgorzata Marjanska; Pierre-Gilles Henry; Patrick J Bolan; Brooks Vaughan; Elizabeth R Seaquist; Rolf Gruetter; Kâmil Uğurbil; Michael Garwood
Journal:  Magn Reson Med       Date:  2005-04       Impact factor: 4.668

Review 3.  The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

Authors:  S E Kahn; S Zraika; K M Utzschneider; R L Hull
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

4.  Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass.

Authors:  G Fontés; B Zarrouki; D K Hagman; M G Latour; M Semache; V Roskens; P C Moore; M Prentki; C J Rhodes; T L Jetton; V Poitout
Journal:  Diabetologia       Date:  2010-07-14       Impact factor: 10.122

Review 5.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

6.  Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.

Authors:  Andrea Kelly; Diva D De Leon; Saba Sheikh; Devaney Camburn; Christina Kubrak; Amy J Peleckis; Darko Stefanovski; Denis Hadjiliadis; Michael R Rickels; Ronald C Rubenstein
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

7.  Different β-cell secretory phenotype in non-obese compared to obese early type 2 diabetes.

Authors:  Lalitha Gudipaty; Nora K Rosenfeld; Carissa S Fuller; Marina Cuchel; Michael R Rickels
Journal:  Diabetes Metab Res Rev       Date:  2020-02-17       Impact factor: 4.876

8.  Beta-cell hypersensitivity for glucose precedes loss of glucose-induced insulin secretion in 90% pancreatectomized rats.

Authors:  J L Leahy; L M Bumbalo; C Chen
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

9.  {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants.

Authors:  Michael R Rickels; Rebecca Mueller; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2010-01-22       Impact factor: 5.958

Review 10.  Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.

Authors:  Piero Marchetti; Roberto Lupi; Silvia Del Guerra; Marco Bugliani; Valentina D'Aleo; Margherita Occhipinti; Ugo Boggi; Lorella Marselli; Matilde Masini
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.